Read by QxMD icon Read


Aleksandr Voskoboinik, Michael C G Wong, Jessica K Elliott, Benedict T Costello, Sandeep Prabhu, Justin A Mariani, Jonathan M Kalman, Peter M Kistler, Andrew J Taylor, Joseph B Morton
INTRODUCTION: CMR-identified late gadolinium enhancement (LGE), representing regional fibrosis, is often used to predict ventricular arrhythmia risk in non-ischemic cardiomyopathy (NICM). However, LGE is more closely correlated with sustained monomorphic ventricular tachycardia (SMVT) than ventricular fibrillation (VF). We characterised CMR findings of ventricular LGE in VF survivors. METHODS: We examined consecutively resuscitated VF survivors undergoing contrast-enhanced 1...
June 22, 2018: Pacing and Clinical Electrophysiology: PACE
Shideh Anvari, Mohammad Ali Akbarzadeh, Fariba Bayat, Mohammad Hasan Namazi, Morteza Safi
BACKGROUND: Implantable cardioverter-defibrillator (ICD) is the most effective therapy currently available to prevent sudden cardiac death (SCD) in patients with left ventricular (LV) dysfunction. Although LV ejection fraction (LVEF) is an excellent marker of SCD in these patients, but determining other predictors might help to identify patients who will be benefit more from device implantation. The purpose of this study was to determine whether abnormal LV sphericity index (SI) in transthoracic echocardiography is associated with appropriate ICD therapy in these patients...
June 21, 2018: Pacing and Clinical Electrophysiology: PACE
Yasushi Wakabayashi, Takeshi Mitsuhashi, Naoyuki Akashi, Takekuni Hayashi, Tomio Umemoto, Yoshitaka Sugawara, Hideo Fujita, Shin-Ichi Momomura
Previous studies suggested that right ventricular pacing was associated with pacing-induced cardiac dysfunction (PICD). The purpose of this study was to investigate the clinical characteristics including the incidence of undiagnosed cardiac sarcoidosis (CS) in patients with atrioventricular block (AVB) who manifest PICD. We retrospectively investigated consecutive patients with permanent pacemaker (PPM) undergoing a first-generator replacement surgery with a new PPM or an upgrade procedure to a cardiac resynchronization therapy (CRT) device between December 1, 2011 and June 30, 2017...
June 21, 2018: Heart and Vessels
Cosmo Godino, Andrea Scotti, Maurizio Taramasso, Marianna Adamo, Marco Russo, Mauro Chiarito, Francesco Melillo, Alessandro Beneduce, Carlo Andrea Pivato, Luca Arrigoni, Evelina Toscano, Anna Salerno, Alberto Cappelletti, Valeria Magni, Stefano Stella, Gabriele Fragasso, Matteo Montorfano, Eustachio Agricola, Federica Ettori, Alberto Margonato, Francesco Maisano, Antonio Colombo
BACKGROUND: MitraClip implantation has evolved as a new tool for treatment of inoperable or high-risk patients with severe functional mitral regurgitation (FMR) due to dilated cardiomyopathy (DCM). Limited data are available regarding MitraClip outcomes comparing patients with ischemic and non-ischemic DCM. METHODS: From 2008 to 2016, 314 patients received MitraClip for FMR at four institutions: Brescia, Zurich and Milan. Patients were stratified according to MR aetiology in non-ischemic FMR (n = 99) and ischemic FMR (n = 215)...
June 12, 2018: International Journal of Cardiology
Fabio V Lima, Suraj Singh, Puja B Parikh, Luis Gruberg
BACKGROUND: Left ventricular end-diastolic pressure (LVEDP) reflects ventricular performance and volume status. We sought to analyze the relationship between LVEDP and the incidence of contrast-induced acute kidney injury (AKI) in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). METHODS: Between January 2006 and December 2008, a total of 254 patients presenting with an acute coronary syndrome had the LVEDP assessed prior to the intervention...
June 9, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
Marina Navarro-Peñalver, M Teresa Perez-Martinez, Manuel Gómez-Bueno, Pablo García-Pavía, Josep Lupón-Rosés, Eulalia Roig-Minguell, Josep Comin-Colet, Antoni Bayes-Genis, Jose A Noguera, Domingo A Pascual-Figal
BACKGROUND: Testosterone deficiency is associated with heart failure (HF) progression and poor prognosis. Testosterone therapy has been shown to improve exercise capacity in patients with chronic HF, but no trial has evaluated the impact of replacement in patients with demonstrated testosterone deficiency. METHODS: Prospective, randomized, double-blind, placebo-controlled, and parallel-group trial comparing testosterone replacement with placebo in males with chronic HF with reduced ejection fraction (HFrEF) and testosterone deficiency (NCT01813201)...
January 1, 2018: Journal of Cardiovascular Pharmacology and Therapeutics
Takashi Kurita, Kenji Ando, Marehiko Ueda, Satoshi Shizuta, Hideo Okamura, Naoki Matsumoto, Bart Gerritse, Dedra H Fagan, Edward J Schloss, Albert Meijer, Angelo Auricchio, Laurence D Sterns, Ken Okumura
BACKGROUND: The PainFree Smart Shock Technology (SST) study showed a low ICD inappropriate shock rate. However, the majority of patients were from Western countries with patient characteristics different from those in Japan. ICD shock rates using the novel SST algorithms in Japanese patients are still unknown. METHODS: All 2,770 patients in the PainFree SST study (Japan [JPN]: N = 181, other geographies [OJPN]: N = 2,589) were included in this analysis. RESULTS: Japanese patients had higher average LVEF (P < 0...
June 21, 2018: Pacing and Clinical Electrophysiology: PACE
Zhi-Hui He, Li-Qun Shao, Li-Ying Xuan, Chun-Gui Wang, Cheng-Xi Wei, Yu Wang, Ming Zhao
OBJECTIVES: To investigate the effect of Astragalus injection on cardiomyocyte apoptosis, endoplasmic reticulum stress and connexin protein in cardiomyopathy rats induced by adriamycin. METHODS: Thirty-six male Wister rats were randomly divided into control group ( n =12), adriamycin(ADR) group ( n =12) and Astragalus group ( n =12). The normal saline (10 ml/kg body weight) was injected intraperitoneally in control group rats, ADR (2 mg/kg body weight) was injected intraperitoneally in ADR group rats, ADR (10 ml/kg body weight) and Astragalus injection (10 ml/kg body weight) were injected intraperitoneally in rats of astragalus group, one time a week, totle 3 times...
February 8, 2018: Chinese Journal of Applied Physiology
Y M Xue, M G Chen, D W Chen, W F Wu, Y L Liu, F H Lin
Objective: To explore the effect of microRNA-21 (miR-21) on myocardial fibrosis in mice with chronic viral myocarditis (CVMC) and related mechanisms. Methods: Forty 4-week-old Balb/c male mice were randomly divided into 4 groups ( n= 10 each): phosphate buffer saline (PBS) group, CVMC group, CVMC+miR-21 inhibitor group, CVMC+isotype control group. The first injection of Coxsackie virus B3 (CVB3) or PBS was performed on day 0, and the total study time was 42 days. Each mouse in CVMC group, CVMC+miR-21 inhibitor group and CVMC+isotype control group was intraperitoneally (i...
June 24, 2018: Zhonghua Xin Xue Guan Bing za Zhi
C X Xu, L Li, S J Gong, Y H Yu, J Yan
Objective: To investigate the effect of levosimendan on cardiac function and prognosis in elderly patients with septic myocardial contractility impairment. Methods: A prospective, randomized, controlled study was conducted. The elderly patients with septic myocardial contractility impairment who were admitted to Intensive Care Unit in Zhejiang Hospital were consecutively enrolled from January 2017 to September 2017. The key inclusive criterion was left ventricular ejection fraction (LVEF) ≤50% after fluid resuscitation...
June 1, 2018: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
Jan Heimeshoff, Constanze Merz, Marcel Ricklefs, Felix Kirchhoff, Axel Haverich, Christoph Bara, Christian Kühn
BACKGROUND:  A wearable cardioverter-defibrillator (WCD) can terminate ventricular fibrillation and ventricular tachycardias via electrical shock and thus give transient protection from sudden cardiac death. We investigated its role after cardiac surgery. METHODS:  We retrospectively analyzed all patients who were discharged with a WCD from cardiac surgery department. The WCD was prescribed for patients with a left ventricular ejection fraction (LVEF) of ≤35% or an explanted implantable cardioverter-defibrillator (ICD)...
June 20, 2018: Thoracic and Cardiovascular Surgeon
Wei Wu, Dong-Xia Li, Qing Wang, Ying Xu, Yun-Jing Cui
Objective: Low-level high-sensitivity cardiac troponin T (hs-cTnT) increases in elderly population. In this study, the relationship between hs-cTnT level and all-cause death of elderly inpatients with non-acute coronary syndrome (non-ACS) after discharge from the hospital was investigated. Materials and methods: Non-ACS patients aged >65 years admitted in the General Practice Wards and Department of Geriatrics of Fuxing Hospital Affiliated to Capital Medical University were enrolled in the study...
2018: Clinical Interventions in Aging
Francisco Fernández-Avilés, Ricardo Sanz-Ruiz, Jan Bogaert, Ana Casado Plasencia, Inmaculada Gilaberte, Ann Belmans, María Eugenia Fernández-Santos, Dominique Charron, Miguel Mulet, Raquel Yotti, Itziar Palacios, Manuel Luque, Rafael Sádaba, J A San Roman, Mariano Larman, Pedro L Sánchez, Juan Sanchis, Manuel F Jimenez-Navarro, Piet Claus, Reem Al-Daccak, Eleuterio Lombardo, José Luis Abad, Olga Delarosa, Lucia Corcostegui, Javier Bermejo, Stefan Janssens
<u>Rationale:</u> Allogeneic cardiac stem cells (AlloCSC-01) have shown protective, immunoregulatory and regenerative properties with a robust safety profile in large animal models of heart disease. <u>Objective:</u> To investigate the safety and feasibility of early administration of AlloCSC-01 in patients with ST-segment elevation myocardial infarction (STEMI). <u>Methods and Results:</u> CAREMI was a phase I/II multicenter, randomized, double-blind, placebo-controlled trial in patients with STEMI, LVEF ≤ 45% and infarct size ≥ 25% of left ventricular (LV) mass by cardiac magnetic resonance (MR), who were randomized (2:1) to receive AlloCSC-01 or placebo through the intracoronary route at day 5-7...
June 19, 2018: Circulation Research
N Wu, G Yang
This study aims to evaluate the effect of sildenafil on pulmonary hypertension (PH) associated with chronic left heart failure. Twenty patients with PH and left heart failure were divided into treatment group (10 cases, with an oral dose of sildenafil 75 mg daily for 8 weeks) and control group (10 cases, with treatment of cardiac glycosides, diuretics, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker and beta-blockers). Left ventricular systolic function (LVEF), the pulmonary artery systolic pressure (PH), the left ventricular fraction shortening (LVFS), the left atrium diameter (LAD) and the left ventricular end-diastolic diameter (LVD) were measured by echocardiography, the left ventricular mass index (LVMI) was also calculated...
May 2018: Journal of Biological Regulators and Homeostatic Agents
Annamaria Iorio, Michele Senni, Giulia Barbati, Stephen J Greene, Stefano Poli, Elena Zambon, Concetta Di Nora, Giovanni Cioffi, Luigi Tarantini, Antonello Gavazzi, Gianfranco Sinagra, Andrea Di Lenarda
AIM: To assess adverse outcomes attributable to non-cardiac co-morbidities and to compare their effects by left ventricular ejection fraction (LVEF) group [LVEF <50% (heart failure with reduced ejection fraction, HFrEF), LVEF ≥50% (heart failure with preserved ejection fraction, HFpEF)] in a contemporary, unselected chronic heart failure population. METHODS AND RESULTS: This community-based cohort enrolled patients from October 2009 to December 2013. Adjusted hazard ratio (HR) and the population attributable fraction (PAF) were used to compare the contribution of 15 non-cardiac co-morbidities to adverse outcome...
June 19, 2018: European Journal of Heart Failure
Malgorzata Kobusiak-Prokopowicz, Justyna Krzysztofik, Konrad Kaaz, Beata Jolda-Mydlowska, Andrzej Mysiak
The aim of the study was to assess MMP-2 (matrix metalloproteinase-2) and TIMP-2 (tissue inhibitor of metalloproteinase-2) serum levels in patients with diverse types of heart failure (HF) and chronic kidney disease (CKD). 101 patients with chronic HF were enrolled. Each patient has assessed the serum levels of MMP-2, TIMP-2, and NT-proBNP. Patients were initially classified into 2 groups based on their LVEF. 43 patients were classified into the HFREF group (HF with Reduced Ejection Fraction) and 58 characterized as HFPEF (HF with Preserved Ejection Fraction)...
2018: Open Medicine (Warsaw, Poland)
Nobila Valentin Yaméogo, André Koudnoaga Samadoulougou, Larissa Justine Kagambèga, Koudougou Jonas Kologo, Georges Rosario Christian Millogo, Anna Thiam, Charles Guenancia, Patrice Zansonré
BACKGROUND: The aim of this study was to describe maternal and fetal outcomes after pregnancy complicated by peripartum cardiomyopathy (PPCM). METHODS: We included women that had subsequent pregnancy (SSP) after PPCM and assessed maternal prognosis and pregnancy outcomes, in-hospital up to one week after discharge. Clinical and echocardiographic data were collected comparing alive and deceased women. Factors associated with pregnancy outcomes were assessed. RESULTS: Twenty-nine patients were included, with a mean age of 26...
June 18, 2018: BMC Cardiovascular Disorders
Ahmet Karakurt, Cennet Yildiz, Abdülmelik Yildiz, Yavuz Karabağ, Metin Çağdaş, İbrahim Rencüzoğulları, İnanç Artaç, Doğan İliş
OBJECTIVE: To evaluate left atrial (LA) deformation parameters strain (S)/strain rate (SR) and time to peak S/SR obtained by two-dimensional speckle tracking echocardiography (2D-STE) in patients with hypertension for three LA mechanical phases and to compare them with the same indices in the control subjects. METHODS: Fifty-five patients with hypertension (HT) and 29 healthy controls were included in the study. All patients had normal LA poster-anterior diameter, LA and left ventricular ejection fractions (LVEF >50%) in two-dimensional echocardiography (2-DE)...
June 18, 2018: Acta Cardiologica
Şerafettin Demir, Hüseyin Ede, Mehmet Kaplan, Fethi Yavuz, Ceyhun Yücel, İbrahim Halil Kurt
OBJECTIVE: The aim of this study is research relation of serum neopterin level with mortality and morbidity due to systolic HF and also its role in diagnosis of patients with systolic HF. MATERIAL AND METHODS: Eighty-one patients with systolic heart failure (HF group) and eighty-one age- and gender-matched healthy subjects (the control group) were enrolled in the study. Echocardiographic examination was performed accordingly. At the beginning of the study, serum B type natriuretic peptide (BNP), neopterin, and high sensitive C-reactive protein (hs-CRP) were measured accordingly...
June 18, 2018: Acta Cardiologica
Quentin Jacquinot, Sophie Paget-Bailly, Pierre Fumoleau, Gilles Romieu, Jean Yves Pierga, Marc Espié, Alain Lortholary, Jean Marc Nabholtz, Celine Faure Mercier, Iris Pauporté, Julie Henriques, Xavier Pivot
BACKGROUND: Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT00381901). METHODS: LVEF assessment was performed every 3 months while patients received trastuzumab and after completion of treatment over the first 2 years and then every 6 months afterwards. The fluctuations of LVEF over time were described and a logistic regression model was performed investigating associated factors to LVEF perfect recovery at baseline value...
June 15, 2018: Breast: Official Journal of the European Society of Mastology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"